Transcription factor LSF-DNMT1 complex dissociation by FQI1 leads to aberrant DNA methylation and gene expression

Oncotarget. 2016 Dec 13;7(50):83627-83640. doi: 10.18632/oncotarget.13271.

Abstract

The transcription factor LSF is highly expressed in hepatocellular carcinoma (HCC) and promotes oncogenesis. Factor quinolinone inhibitor 1 (FQI1), inhibits LSF DNA-binding activity and exerts anti-proliferative activity. Here, we show that LSF binds directly to the maintenance DNA (cytosine-5) methyltransferase 1 (DNMT1) and its accessory protein UHRF1 both in vivo and in vitro. Binding of LSF to DNMT1 stimulated DNMT1 activity and FQI1 negated the methyltransferase activation. Addition of FQI1 to the cell culture disrupted LSF bound DNMT1 and UHRF1 complexes, resulting in global aberrant CpG methylation. Differentially methylated regions (DMR) containing at least 3 CpGs, were significantly altered by FQI1 compared to control cells. The DMRs were mostly concentrated in CpG islands, proximal to transcription start sites, and in introns and known genes. These DMRs represented both hypo and hypermethylation, correlating with altered gene expression. FQI1 treatment elicits a cascade of effects promoting altered cell cycle progression. These findings demonstrate a novel mechanism of FQI1 mediated alteration of the epigenome by DNMT1-LSF complex disruption, leading to aberrant DNA methylation and gene expression.

Keywords: DNA methylation; HCC; gene expression; transcription factor LSF.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Benzodioxoles / pharmacology*
  • CCAAT-Enhancer-Binding Proteins / genetics
  • CCAAT-Enhancer-Binding Proteins / metabolism
  • COS Cells
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / enzymology
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / pathology
  • Cell Cycle / drug effects
  • Cell Proliferation / drug effects
  • Chlorocebus aethiops
  • CpG Islands
  • DNA (Cytosine-5-)-Methyltransferase 1 / genetics*
  • DNA (Cytosine-5-)-Methyltransferase 1 / metabolism
  • DNA Methylation / drug effects*
  • DNA-Binding Proteins / genetics*
  • DNA-Binding Proteins / metabolism
  • Epigenesis, Genetic / drug effects*
  • Gene Expression Regulation, Neoplastic / drug effects*
  • HEK293 Cells
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / enzymology
  • Liver Neoplasms / genetics
  • Liver Neoplasms / pathology
  • Protein Binding
  • Quinolones / pharmacology*
  • Transcription Factors / genetics*
  • Transcription Factors / metabolism
  • Transfection
  • Ubiquitin-Protein Ligases

Substances

  • 8-(2-ethoxyphenyl)-7,8-dihydro-(1,3)dioxolo(4,5-g)quinolin-6(5H)-one
  • Antineoplastic Agents
  • Benzodioxoles
  • CCAAT-Enhancer-Binding Proteins
  • DNA-Binding Proteins
  • Quinolones
  • TFCP2 protein, human
  • Transcription Factors
  • DNA (Cytosine-5-)-Methyltransferase 1
  • DNMT1 protein, human
  • UHRF1 protein, human
  • Ubiquitin-Protein Ligases